Oil Japan Agro Research Co., Ltd.
Basic information
- Head office
- 1405 Gotanda, Koka Town, Koka City, Shiga Prefecture
- Chief executive
- Eisaku Nanohana
- Capital
- 10,000,000 JPY
- Employees (non-consolidated)
- Employees (consolidated)
- 41 people
- Start date
- 2004-02-26
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| SHIONOGI Group Worldwide |
Network
History
Founder Yoshisaburo Shio no established Shio no Yoshisaburo Store in Doushū-cho, Osaka, selling traditional and Western medicines.![]()
Shionogi Yoshimasa founded the drug wholesaler 'Shionogi Yoshimasa Shop' on March 17, 1878, at 3-12 Motosho-cho, Osaka.![]()
Manufactured and sold in-house new drug No.1 antacid 'Antachijin'; trademark registered with the 'Bento' mark.![]()
Yoshimasa's second son, Nagajiro, began trial production of an antacid and succeeded in commercializing it. This became the company's first self-developed new drug 'Antachijin'.![]()
Yoshimasa built the Shionogi Pharmaceutical Plant in Nishinari-ku, Osaka Prefecture, and began full operations in 1910.![]()
Merged Shio Yoshisaburo Store and Shio Pharmaceutical Plant, reorganized into Shio Yoshishō Store Co., Ltd.![]()
Established Kase Factory in Amagasaki, Hyogo Prefecture (now Kase Office); set up a laboratory inside the factory.![]()
In 1945, after the war, the drug wholesaler Shionogi Yoshimasa Shop and the pharmaceutical business Shionogi Pharmaceutical Plant merged to form 'Shionogi Yoshimasa Shop Co., Ltd.'.![]()
In response to the post-war management crisis, Yoshimasa implemented management improvement measures such as technology upgrades and cost reductions, advancing rationalization.![]()
Since its founding, the company has continued to emphasize producing better products, accurate sales, and technological advancement as part of its corporate culture.![]()
Constructed Central Research Institute in Fukushima-ku, Osaka City (now consolidated into the Pharmaceutical Research Center).![]()
Established the Animal Pharmaceutical Department (transferred in 2002), established the Plant Pharmaceutical Department (transferred in 2001), commenced operations of the Clinical Laboratory (transferred in 2002): Established Shionogi Taiwan Pharmaceutical Co., Ltd.![]()
Construction of Shionogi Shibuya Building (Shibuya-ku, Tokyo): Construction of New Drug Research Institute (Toyonaka City, Osaka Prefecture) (now Pharmaceutical Research Center).![]()
Construction of Medical Science Research Institute (within Settsu Factory site) (now consolidated into Pharmaceutical Research Center): Release of oxacillin-type antibiotic 'Furamarin'.![]()
Established Shionogi General Service Co., Ltd. (now Shionogi Business Partner Co., Ltd.): Acquired capsule business from Eli Lilly (sold in 2005).![]()
Establishment of Shionogi Code of Conduct (revised 2012): Founded Oomori Pharmaceutical Co., Ltd. (sold in 2002): Established Musshu Pharmaceutical Co., Ltd. (sold in 2010).![]()
To focus on the pharmaceutical business, the company transferred plant medicines, animal medicines, and pharmaceutical wholesale to other companies, accelerating research and development and advancing overseas expansion.![]()
Established Shionogi USA, Inc. (now Shionogi Inc.): Overseas JV: Established Shionogi-GlaxoSmithKline Pharmaceuticals LLC (later Shionogi-ViiV Healthcare LLC) and began joint research and development of HIV treatment drugs.![]()
Start of Second Medium-Term Management Plan: Release of high cholesterol treatment drug 'Crestol': Release of carbapenem antibiotic 'Finibax'.![]()
A development subsidiary was established in the United States, and a joint drug development program was launched with GlaxoSmithKline in the United Kingdom.![]()
Established Shionogi Analytical Center Co., Ltd.: Release of cancer pain treatment granule 'Okinome'.![]()
Acquired US-based Sciele Pharma, Inc. (now Shionogi Inc.): Established joint research facility with Hokkaido University, Shionogi Drug Innovation Center: Release of hypertension treatment drug 'Ilbetan': Release of acne treatment drug 'Defirin': Release of idiopathic pulmonary fibrosis treatment drug 'Pirespa'.![]()
Start of Third Medium-Term Management Plan: Established Shionogi Techno Advance Research Co., Ltd.: Established Osaka University Graduate School of Medicine-affiliated PET Molecular Imaging Center: Release of anti-influenza virus drug 'Rapiacta': Release of antidepressant 'Sainbarta'.![]()
Acquired Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Ltd.: Constructed new building SPRC4 within the Pharmaceutical Research Center (SPRC) and consolidated drug discovery research functions.![]()
The company acquired the Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited.![]()
Established European subsidiary Shionogi Limited (UK) : Signed a new framework agreement with Vibe Healthcare regarding HIV treatment drugs : Launched cancer pain treatment injectable 'Oxfast' : Launched hypertension drug 'Aimix'.![]()
Established Beijing Shionogi Pharmaceutical Technology Co., Ltd. (China) : Established Shionogi Singapore Pte. Ltd. : Modified royalty agreement for Crestol with AstraZeneca : Launched postmenopausal vaginal atrophy drug 'Osphena' in the United States : Launched hypertension drug 'Iltra'.![]()
Launched mid-term management plan 'Shionogi Growth Strategy 2020 (SGS2020)' : Launched HIV treatment drug 'Tebikei'.![]()
Aiming for growth as a drug discovery-based pharmaceutical company, a medium-term management plan based on ROE was formulated, advancing flexible business development responsive to environmental changes.![]()
Launched HIV treatment drug 'Triemek' : Launched allergen immunotherapy drug 'Asitia' : Launched thrombocytopenia treatment drug 'Mulpreta'.![]()
Updated mid-term management plan 'SGS2020' : Established Shionogi Healthcare Co., Ltd. : Launched high cholesterol drug 'Crestol OD tablets'.![]()
Established domestic group companies: Shionogi Career Development Center Co., Ltd., Shionogi Digital Science Co., Ltd., Shionogi Business Partner Co., Ltd., Shionogi Pharma Pharmacovigilance Center Co., Ltd., Shionogi Marketing Solutions Co., Ltd. : Launched cancer pain treatment drug 'Mesapain' : Launched ADHD treatment drug 'Inchunib' : Launched opioid-induced constipation treatment drug 'Symproic' in the United States : Launched opioid-induced constipation treatment drug 'Soinproik' : Launched sustained cancer pain treatment drug 'Oxycontin TR tablets'.![]()
Established Shionogi Pharma Co., Ltd. : Established European subsidiary Shionogi B.V. : Launched anti-influenza drug 'Zoflura' : Launched thrombocytopenia treatment drug 'Mulpleta' in the United States : Launched anti-HIV drug 'Jaruka'.![]()
Established joint venture 'Stream-I Co., Ltd.' with M3 : Consolidated UMN Pharma Co., Ltd. as a subsidiary : Opened Shionogi Education and Training Center in Amagasaki City : Launched opioid-induced constipation treatment drug 'Rizmoic' in Europe : Launched anti-influenza drug 'Shufukou' in Taiwan : Launched ADHD treatment drug 'Vivance'.![]()
Launched mid-term management plan 'Shionogi Transformation Strategy 2030 (STS2030)' : Established joint venture 'Ping An Shionogi Co., Ltd.' with Ping An Insurance : Fully acquired Tetra Corp. in the United States : Acquired Nagase Pharmaceutical as a subsidiary through Shionogi Pharma : Launched gram-negative bacterial infection drug 'Fetroja' in the United States : Launched gram-negative bacterial infection drug 'Fetcroja' in Europe.![]()
Launched wastewater epidemiology service for COVID-19 : Launched opioid-induced constipation treatment drug 'Soinproik' in Taiwan.![]()
Established joint venture 'AdvanSentinel Co., Ltd.' with Shimadzu Corporation : Established General Foundation 'Shionogi Infectious Disease Research Promotion Foundation' : Built SHIONOGI Group brand and established group brand mark : Established Yui Connection Co., Ltd. : Launched COVID-19 treatment drug 'Zokova'.![]()
News
There is no news.
Public records
National Tax Agency basic information2160001005740
- Trade name
- 油日アグロリサーチ株式会社
- Trade name (kana)
- アブラヒアグロリサーチ
- Name in English
- Corporation type
- 301
- Address
- 〒520-3423 滋賀県甲賀市甲賀町五反田1405番地
- Postal code
- 5203423
- Prefecture code
- 25
- City code
- 209
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2018-06-28
- Change date
- 2015-10-05
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 01
- Correction type
- 1
- Trade name image ID
- Address image ID
- Sequence number
- 3830871
METI gBizINFO2160001005740
- Corporate number
- 2160001005740
- Trade name
- 油日アグロリサーチ株式会社
- Trade name (kana)
- アブラヒアグロリサーチ
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 滋賀県甲賀市甲賀町五反田1405番地
- Postal code
- 5203423
- Prefecture
- 滋賀県
- Prefecture code
- 25
- City or district
- 甲賀市
- City code
- 209
- Street address
- 甲賀町五反田1405番地
- Organisation type
- 301
- Processing type
- 01
- Correction type
- 1
- Status
- Representative
- Capital
- Employees
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2018-06-28
- Key information
- 2160001005740